摘要
目的 探讨慢性阻塞性肺疾病（COPD）稳定期应用沙美特罗替卡松粉吸入治疗对急性加重期血气的影响.方法 34例从未正规使用吸入糖皮质激素＋吸入长效β2受体激动剂联合治疗的中、重度COPD患者,前一次慢性阻塞性肺疾病急性加重期（AECOPD）发病病情稳定后应用沙美特罗替卡松粉吸入剂（舒利迭）治疗直至因发生AECOPD再次入院.观察两次的pH、动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）值的比较.结果 后一次PaO2显著高于前一次住院PaO2（P＜0.05）;后一次PaCO2显著低于前一次PaCO2值（P＜0.05）,前后两次pH比较差异无统计学意义.结论 中、重度COPD稳定期吸入沙美特罗50μg/丙酸氟替卡松500μg复方制剂可以明显改善AECOPD患者的病情严重程度和血气指标.
Objective Discuss the effect of the Salmeterol/Fluticasone powder inhalational treatment on acute exacerbation phase blood gases at the stable phase of chronic obstructive pulmonary disease（COPD）. Methods Thirty-four cases of middle and advanced COPD patients who had never received the combination therapy of the inhalational glucocorticoid and long-acting β2 receptor stimulant were treated with the Salmeterol/Fluticasone powder inhalation （retiedde） until admitted to hospital again due to the occurrence of acute exacerbation chronic obstructive pulmonary disease （AECOPD）. Observe the comparison of the pH, arterial partial pressure of oxygen （PaO2） and arterial partial pressure of carbon dioxide （PaCO2） values of the two hospitalizations. Results The latter hospitalization PaO2 was significantly higher than the previous PaO2 （ P 〈0.05）. The latter PaCO2 was significantly higher than the previous PaCO2 （P 〈0.05）. And the two hospitalization pH values had no significant difference.Conclusions The inhalation of Salmeterol 50μg/Fluticasone 500 μg compound preparation at the middle and advanced COPD stable phase will significantly improve the patients＇ condition and blood gases during the AECOPD.
出处
《国际呼吸杂志》
2010年第21期1285-1286,共2页
International Journal of Respiration
关键词
沙美特罗替卡松
慢性阻塞性肺疾病
稳定期
急性加重期
血气
Salmeterol/Fluticasone
Chronic obstructive pulmonary disease
Stable phase
Acute exacerbation phase
Blood gases
